What Makes RHA® Unique? Redefining Hyaluronic Acid injectables
The Science Behind Natural Beauty
Mastering Movement: Redefining Rheological Parameters with RHA® Technology
Test

RHA® 10 Years 

Our advanced technology, adapted from a patented1 process and cutting-edge research, is at the heart of our dermal fillers and dermocosmetics. 

Test

What Makes RHA® Unique? 

Discover the science of Teoxane’s Resilient Hyaluronic Acid® (RHA®), for dynamic, natural results.2

Test

The Science Behind Natural Beauty 

Teoxane’s “Preserved Network Technology” is a revolutionary heatless3 process that has transformed the creation of hyaluronic acid gels. 

Test

Mastering Movement 

Explore how Teoxane’s expertise in rheology delivers hyaluronic acid gels engineered for natural, dynamic aesthetic results. 2

Follow us
  • Instagram
  • LinkedIn
  • Facebook
  • YouTube
Contact us

Need to report a problem?
We are here for you

The Teoxane cosmetics comply with the requirements of the European regulation 1223/2009. Cosmetic products are not designed to be injected.

RHA 10 years – Aesthetic Innovation in Motion

 References:

Medical devices for professional use only. Product indications and availability vary from country to country. Please consult product instructions locally approved for more information.

Medical devices are regulated health products bearing the CE mark, CE2797, under the Medical Device Regulation (EU) 2017/745.

Contact for materiovigilance notification: medical@teoxane.com.

 

 

  1. Process for preparing a crosslinked gel: Patent No US 9,353,194 B2 ; WO2010/131175 A1
  2. Faivre F, et al. "Advanced concepts in rheology for the evaluation of hyaluronic acid–based soft tissue fillers." Dermatologic Surgery 47.5 (2021): e159.
  3. Vantou et al. Unravelling the key characteristics of the Preserved Network Technology (PNT) : Manufacturing the dynamic RHA fillers

Celebrating 10 Years of RHA: Beauty in Motion, Powered by Science

References

Medical devices for professional use only. Product indications and availability vary from country to country. Please consult product instructions locally approved for more information.

Medical devices are regulated health products bearing the CE mark, CE2797, under the Medical Device Regulation (EU) 2017/745.

Contact for materiovigilance notification: medical@teoxane.com.

  1. FDA Executive Summary General Issues Panel Meeting on Dermal Fillers - March 23, 2021
  2. Micheels P. et al. Journal of Drugs in Dermatology: JDD (2017);16(2):154-161
  3. Faivre F, et al. "Advanced concepts in rheology for the evaluation of hyaluronic acid–based soft tissue fillers." Dermatologic Surgery 47.5 (2021): e159.
  4. Rzany B, Converset-Viethel S, Hartmann M, Larrouy JC, Ribé N, Sito G, Noize-Pin C. Efficacy and Safety of 3 New Resilient Hyaluronic Acid Fillers, Crosslinked With Decreased BDDE, for the Treatment of Dynamic Wrinkles: Results of an 18-Month, Randomized Controlled Trial Versus Already Available Comparators. Dermatol Surg. 2019 Oct;45(10):1304-1314 
  5. Data on file. Teoxane sales 2015-2024
  6. Data on file. Clinical Experimental Report (CER) Teosyal®

What does RHA mean?

 

References

Medical devices for professional use only. Product indications and availability vary from country to country. Please consult product instructions locally approved for more information.

Medical devices are regulated health products bearing the CE mark, CE2797, under the Medical Device Regulation (EU) 2017/745.

Contact for materiovigilance notification: medical@teoxane.com.

 

  1. Faivre J, et al. Advanced concepts in rheology for the evaluation of hyaluronic acid–based soft tissue fillers. Dermatologic Surgery 47.5 (2021): e159 
  2. Teoxane. UK Wellness Report, DRG. 2022.
  3. Matsumoto, D. "Reading facial expressions of emotion." 2011.
  4.  https://www.paulekman.com/resources/micro-expressions/
  5. Vantou et al. Unravelling the key characteristics of the Preserved Network Technology (PNT) : Manufacturing the dynamic RHA fillers

How RHA Gels Are Made: A Masterpiece of Science and Innovation

References

Medical devices for professional use only. Product indications and availability vary from country to country. Please consult product instructions locally approved for more information.

Medical devices are regulated health products bearing the CE mark, CE2797, under the Medical Device Regulation (EU) 2017/745.

Contact for materiovigilance notification: medical@teoxane.com.

 

*BDDE = 1,4-Butanediol diglycidyl ether 

  1. Process for preparing a crosslinked gel: Patent No US 9,353,194 B2 ; WO2010/131175 A1
  2. Vantou et al. Unravelling the key characteristics of the Preserved Network Technology (PNT) : Manufacturing the dynamic RHA fillers
  3. Faivre J, Pigweh AI, Iehl J, Maffert P, Goekjian P, Bourdon F. Crosslinking hyaluronic acid soft-tissue fillers: current status and perspectives from an industrial point of view. Expert Rev Med Devices. 2021 Dec;18(12):1175-1187

The RHA® Collection by Teoxane

References

Medical devices for professional use only. Product indications and availability vary from country to country. Please consult product instructions locally approved for more information.

Medical devices are regulated health products bearing the CE mark, CE2797, under the Medical Device Regulation (EU) 2017/745.

Contact for materiovigilance notification: medical@teoxane.com.

 

*Average duration depends on several factors: patients’ skin type, wrinkle severity, injection type and volume

 

  1. Faivre J, Gallet M, Tremblais E, Trévidic P, Bourdon F. 5. Advanced Concepts in Rheology for the Evaluation of Hyaluronic Acid-Based Soft Tissue Fillers. Dermatol Surg. 2021 May 1;47(5):e159-e167
  2. TEOSYAL RHA® 1 – Instructions For Use
  3. TEOSYAL RHA® 2 – Instructions For Use
  4. TEOSYAL RHA® 3 – Instructions For Use
  5. TEOSYAL RHA® 4 – Instructions For Use
  6. TEOSYAL RHA® KISS – Instructions For Use
  7. Rzany B, et al. Efficacy and Safety of 3 New Resilient Hyaluronic Acid Fillers, Crosslinked With Decreased BDDE, for the Treatment of Dynamic Wrinkles: Results of an 18-Month, Randomized Controlled Trial Versus Already Available Comparators. Dermatol Surg. 2019;45(10):1304-1314
  8. Sundaram H et al, «Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A-Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations,» Plast Reconstr Surg, pp. 137(5): p. 1410-23, 2016.